Barclays
ACRS icon

Barclays’s Aclaris Therapeutics ACRS Stock Holding History

Barclays’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100,000
Closed -$809K – 4506
2023
Q1 		$809K Buy
+100,000
New +$1.27M ﹤0.01% 2897

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Barclays's ACRS Position: Q2 2026 in Review

Barclays increased its Aclaris Therapeutics (ACRS) stake by 239% in Q2 2026, buying an estimated $230K and bringing the position to 73,010 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #3357.

Barclays first reported a position in ACRS in Q4 2015 and has held it in 40 quarters since. The position peaked at $1.6M in Q3 2023. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Barclays held 73,010 shares of Aclaris Therapeutics worth $386K as of Q2 2026.
  • Barclays bought 51,502 Aclaris Therapeutics shares in Q2 2026, an estimated $230K.
  • Aclaris Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3357 holding.
  • Barclays first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 40 quarters since.
  • Barclays's Aclaris Therapeutics position peaked at $1.6M in Q3 2023.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.